Passage Bio, Inc.
Key Metrics
- Previous Close
- $4.22
- 52-Week Range
- $3.29 – $20.00
- Market Cap
- $13.31M
- P/E (TTM)
- —
- EPS (TTM)
- -10.35
- Dividend Yield
- 0.00%
Advanced Metrics
- Price/Book
- 258.44
- PEG Ratio
- —
- Return on Equity
- -212.27%
- Return on Assets
- -45.26%
- Gross Margin
- 0.00%
- Operating Margin
- 0.00%
- Profit Margin
- 0.00%
- Current Ratio
- 1.00
- Debt/Equity
- —
- Total Debt
- $0.00
- Free Cash Flow
- $-14.79M
- Revenue Growth
- —
- Earnings Growth
- —
- Enterprise Value
- $-6.85M
Market Snapshot
About
Passage Bio is a clinical-stage genetic medicines company focused on developing AAV-delivered gene therapies for central nervous system disorders. The company leverages its platform to target rare neurological diseases with potentially transformative one-time treatments, aiming to address significant unmet medical needs in CNS conditions.